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Abstract
The optimum treatment for prosthetic joint infections has not been clearly deﬁned. We report our experience of the management of
acute haematogenous prosthetic joint infection (AHPJI) in patients during a 3-year prospective study in nine Spanish hospitals. Fifty
patients, of whom 30 (60%) were female, with a median age of 76 years, were diagnosed with AHPJI. The median infection-free period fol-
lowing joint replacement was 4.9 years. Symptoms were acute in all cases. A distant previous infection and/or bacteraemia were identiﬁed
in 48%. The aetiology was as follows: Staphylococcus aureus, 19; Streptococcus spp., 14; Gram-negative bacilli, 12; anaerobes, two; and mixed
infections, three. Thirty-four (68%) patients were treated with a conservative surgical approach (CSA) with implant retention, and 16 had
prosthesis removal. At 2-year follow-up, 24 (48%) were cured, seven (14%) had relapsed, seven (14%) had died, ﬁve (10%) had persistent
infection, ﬁve had re-infection, and two had an unknown evolution. Overall, the treatment failure rates were 57.8% in staphylococcal
infections and 14.3% in streptococcal infections. There were no failures in patients with Gram-negative bacillary. By multivariate analysis,
CSA was the only factor independently associated with treatment failure (OR 11.6; 95% CI 1.29–104.8). We were unable to identify
any factors predicting treatment failure in CSA patients, although a Gram-negative bacillary aetiology was a protective factor. These
data suggest that although conservative surgery was the only factor independently associated with treatment failure, it could be the
ﬁrst therapeutic choice for the management of Gram-negative bacillary and streptococcal AHPJI, and for some cases with acute S. aureus
infections.
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Prosthetic joint infection (PJI) is an uncommon complication
(1–2%) of joint replacement surgery, and is associated with
high morbidity and medical cost [1–7]. Successful treatment
of chronic PJI often requires prosthesis removal and
prolonged antimicrobial therapy. Acute PJIs are less likely to
be associated with complete bioﬁlm development or loosen-
ing of the implant; thus, there is a chance of cure without
prosthesis removal. In acute infections, a conservative surgi-
cal approach (CSA) may be appropriate if it is combined with
prolonged pathogen-targeted therapy [1–5,7–20]. However,
the usefulness of a CSA has not been extensively evaluated,
because the number of patients included in reported series
is small, and acute postoperative and haematogenous PJI
(AHPJI) have usually been analysed together. We review our
experience in the treatment of AHPJI, focusing on patients
treated with a CSA without prosthesis removal, to identify
risk factors associated with treatment failure.
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE INFECTIOUS DISEASES
Patients and Methods
Study population and deﬁnitions
From January 2004 to December 2006, all patients with PJI
were prospectively evaluated in nine Spanish hospitals
included in the REIPI (Spanish Network for Research in
Infectious Disease) programme. As this was an observational
study, patients were not randomized to any surgical modality
or antibiotic treatment. A standardized case report form was
used to abstract medical records. For the present study, we
focused on patients with AHPJI.
PJI was classiﬁed as AHPJI according to the criteria of
Tsukayama et al. [21], modiﬁed by Crockarell et al. [22], i.e.
acute onset of symptoms more than 1 month after total joint
replacement in a patient in whom the prosthesis had previ-
ously been functioning well. A prosthetic joint was classiﬁed
as infected by the presence of at least one of the following
clinical signs and symptoms: (i) repeated growth of the same
microorganism from cultures of joint aspirate or peripros-
thetic tissue; (ii) positive blood cultures; and (iii) purulence
surrounding the prosthesis at the time of surgery or identi-
ﬁed by joint ﬂuid aspiration.
Surgical treatment was classiﬁed as conservative when it
involved retention of the prosthesis, and non-conservative
when it involved removal of all components of the implant.
Adequate antibiotic therapy was deﬁned as administration
of appropriate antimicrobial agents according to susceptibility
testing results for at least 8 weeks. In all cases, an infectious
disease staff member participated in the management of
these patients.
The initial assessment of improvement was based on the
disappearance of clinical and biological signs at the end of
medical treatment. Response to therapy was deﬁned as fol-
lows: (i) cured—improvement with no apparent relapse at
24 months of follow-up; (ii) persistence—absence of
improvement or initial improvement followed by reappear-
ance of signs of infection during the initial planned course of
antibiotic therapy and repeat isolation of the same micro-
organism, requiring chronic suppressive antibiotic therapy; (iii)
relapse—initial improvement and then recurrence of infec-
tion with the same microorganism following discontinuation
of antibiotic therapy within the 24-month follow-up period;
or (iv) re-infection—initial improvement followed by recur-
rence of infection by a different microorganism within the
follow-up period. Death was classiﬁed as related or unre-
lated to prosthesis infection. Treatment failure was deﬁned
as follows: (i) persistence of infection needing chronic sup-
pressive therapy; (ii) relapse of infection during follow-up; or
(iii) death due to prosthesis-related infection.
Statistical analysis
Statistical analyses were performed with the SPSS software
package (version 13.0). Categorical variables are expressed
as percentages, and numerical data as the mean (with
standard deviation (SD)), median, and range. Categorical
variables were compared with the chi-square test or Fisher’s
exact test (two-tailed), and continuous variables with the
unpaired Student t-test. CSA patients were compared with
those with prosthesis removal by comparing the time to
treatment failure by use of a Kaplan–Meier analysis, and
curves were then compared using the log-rank test. Stepwise
multivariate logistic analysis was performed to identify pre-
dictors of treatment failure. A P-value of <0.05 was consid-
ered to be statistically signiﬁcant in the multivariate model.
Results
Study population and clinical presentation
Among 500 PJIs occurring over the 3-year study period, 50
(10%) episodes in 50 patients were considered to be AHPJIs.
The median age of patients with this condition was 76 years
(range, 31–92 years). Treatment was for infection of total knee
replacement in 30 (60%), total hip replacement in 19 (38%), and
a prosthetic shoulder joint in one (2%). Following total joint
replacement, patients had a median infection-free period of
4.9 years (range, 0.3–18.7 years). All patients presented with
an acute onset of symptoms. Sinus tract was present in only
one case, and prosthesis loosening in seven. Demographic
data, comorbid conditions, risk factors predisposing to PJI and
symptoms at presentation are shown in Table 1.
Microbiological ﬁndings
The microbiological ﬁndings of 50 episodes of AHPJI are out-
lined in Table 2. Staphylococcus aureus (38%) and Streptococcus
spp. (28%) were the most commonly isolated microorganisms.
Medical therapy
Patients were treated with speciﬁc antibiotics according to
the susceptibility pattern of the isolated microorganism for a
mean of 15.9 weeks (SD: 11.4) in CSA patients and
10.5 weeks (SD: 7.4) in non-CSA patients (p 0.54). Among
45 patients who survived and completed antibiotic therapy,
36 (78%) received more than 8 weeks of adequate anti-
microbial treatment.
S. aureus infections were treated for a mean of 18.1 weeks
(SD: 11.4). In all but one patient, methicillin-susceptible S. aur-
eus infections were treated initially with intravenous cloxacillin
combined with rifampicin (600–900 mg/day), followed by an
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oral quinolone (levoﬂoxacin at 500–750 mg/day) plus rifampi-
cin (600–900 mg/day) (74%) or co-trimoxazole (trimetho-
prim/sulfamethoxazole, 160/800 mg three times daily) plus
rifampicin (600–900 mg/day). Two patients with methicillin-
resistant S. aureus (MRSA) infection received a glycopeptide
followed by co-trimoxazole (trimethoprim/sulfamethoxazole,
160/800 mg three times daily) plus rifampicin (600–900 mg/
day). Infections due to Streptococcus spp. were treated for a
mean of 10.1 weeks (SD: 6.6) with an intravenous b-lactam,
followed by oral amoxycillin in six cases. Infections due to
Gram-negative bacilli were treated for a mean of 14.7 weeks
(SD: 6.1), mainly with ﬂuoroquinolones (ciproﬂoxacin 750 mg
twice daily) preceded by intravenous cephalosporins.
Surgical treatment
Surgery was performed in 50% of patients within 7 days of
the onset of symptoms. Thirty-four patients were treated
with a CSA (early debridement in 25, and joint aspiration of
purulent drainage in nine), and 16 had prosthesis removal
(two-stage exchange arthroplasty in nine, and deﬁnitive
resection arthroplasty in seven). Outcomes according to the
type of surgical management are shown in Fig. 1.
Outcome analysis
At 2 years of follow-up, 24 (48%) patients were cured, seven
(14%) had relapsed (one ultimately died), seven (14%) had
died (three from PJI, and four from unrelated causes), ﬁve
(10%) had persistent infection requiring chronic suppres-
sive antimicrobial therapy, ﬁve (10%) were re-infected with a
different microorganism, and two (4%) had an unknown
evolution.
Overall, the treatment failure rates were 11 of 19 (57.8%)
for staphylococcal infection, two of 14 (14.3%) for strepto-
coccal infection, and zero of 12 (0%) for Gram-negative
bacillary infection. On Kaplan–Meier survival analysis, the
cumulative probability of treatment failure in patients treated
with prosthesis retention was signiﬁcantly worse (p 0.023)
than in those with prosthesis removal (Fig. 2).
On univariate analysis, factors signiﬁcantly associated with
treatment failure were CSA and S. aureus infection, whereas
a Gram-negative aetiology was a protective factor (Table 3).
On multivariate analysis, CSA was the only factor indepen-
dently associated with treatment failure (OR 11.6;
95% CI 1.29–104.8). Among the seven cases with signs of
prosthesis loosening, three died early, so the outcome could
not be evaluated, and four were treated with prosthesis
removal and were cured.
As better outcome with prosthesis removal was predict-
able, we performed an independent analysis of the 34 CSA
patients, who included 14 (41%) with treatment failure. All
TABLE 2. Microbiological ﬁndings in 50 patients with acute











Staphylococcus aureusa 16 (32) 3 (6) 19 (38)
Streptococcus spp.b 6 (12) 8 (16) 14 (28)
Gram-negative bacillic 8 (16) 4 (8) 12 (24)
Polymicrobial infectionsd 3 (6) 0 3 (6)
Anaerobic infectionse 1 (2) 1 (2) 2 (4)
Total 34 (68) 16 (32) 50 (100)
Data are number (%).
aTwo episodes due to methicillin-resistant strains.
bEight episodes due to Streptococcus agalactiae, two to viridans group strepto-
cocci, one to Enterococcus faecalis, one to Streptococcus pneumoniae, one to Strep-
tococcus bovis, and one to group G streptococci.
cEight episodes due to Escherichia coli, three to Salmonella spp., and one to
Pasteurella multocida.
dOne episode due to methicillin-resistant Staphylococcus aureus and Enterobacter
spp., one to Staphylococcus simulans and Alcaligenes spp., and one to Enterococcus
faecalis and Escherichia coli.
eOne episode due to Bacteroides spp. and one to Peptostreptococcus spp.
TABLE 1. Demographic data, comorbid conditions, risk fac-
tors and symptoms at presentation in 50 episodes of acute
haematogenous prosthetic joint infection
Variable Value
Age (years), median (range) 76 (31–92)
Sex, female/male 30 (60)/20 (40)
Comorbid conditions
Cardiac failure 12 (24)
Rheumatoid arthritis 8 (16)
Diabetes mellitus 7 (14)
Chronic renal failure 7 (14)
Malignancy 6 (12)
Immunosuppressive drugs 4 (8)
Risk factors
Documented bacteraemia due to the
same microorganism
10 (20)
Distant previous infection due to the
same microorganisma
16 (32)
Procedures predisposing to bacteraemiab 3 (6)
Symptoms at presentation
Pain 50 (100)
Inﬂammatory signs 38 (76)
Fever (temperature ‡38C) 35 (70)
Purulence drainage 15 (30)
Biological signs at presentation
Leukocyte count before debridement,
median (range)
12 300 · 109 (1000–27 650)
CRP before debridement, mean (SD), mg/dL 106 (102.4)
ESR before debridement, mean (SD), mm/h 83.5 (28.9)
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; SD, standard
deviation.
Data are number (%), unless otherwise indicate.
aDistant previous infections due to the same microorganism that caused pros-
thetic joint infection: four urinary tract infections (two due to Streptococcus aga-
lactiae and two to Escherichia coli), three cases of infectious enteritis (two due to
Salmonella enteritidis and one to E. coli), two cases of infectious endocarditis due
to Staphylococcus aureus (in both cases, bacteraemia was also documented), two
cases of pneumonia (one due to Streptococcus pneumoniae and 1 to S. aureus),
two cases of cellulitis (one due to S. aureus and one to Pasteurella multocida in
a patient who had been scratched by a cat), one case of cholecystitis, one case
of suppurative adenitis due to methicillin-resistant S. aureus, and one case of
dacryocystitis due to S. aureus.
bProcedures predisposing to bacteraemia include prior dental procedures in two
patients and intravenous drug use in one.
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failures were diagnosed within 6 months of follow-up, except
for one diagnosed within 1 year. Failures were due to S. aur-
eus infection in ten patients, including ﬁve relapses (one
patient died of S. aureus sepsis), two initial infection-related
deaths, and three cases of persistent infection. There was
Streptococcus agalactiae infection in two patients. The remain-
ing two episodes were due to persistent infection with Strep-
tococcus pneumoniae and a polymicrobial cause. Thus, the
failure rate for S. aureus infections treated with a CSA was
62.5% (10/16). The failure rate was ﬁve of 11 (45.4%) for
cases debrided within 7 days of onset of clinical symptoms.
All ﬁve cases drained after 7 days of clinical symptoms had
treatment failure (p <0.093). No treatment failures occurred
among infections due to Gram-negative bacilli. On univariate
analysis, no predictive factors signiﬁcantly associated with
treatment failure were identiﬁed, but Gram-negative bacillary
infection was found to be a protective factor (relative risk
(RR) 0.462; 95% CI 0.305–0.699, p 0.013) (Table 4). The fail-
ure rate in patients with hip prostheses was 41.7% (5/12),
which was similar to that observed in patients with infected
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FIG. 2. Kaplan–Meier estimates of cumulative risk of failure accord-
ing to surgical treatment group. The dashed line represents patients
treated with prosthesis removal (n = 15), and the solid line repre-
sents patients treated with prosthesis retention (n = 33).
TABLE 3. Univariate and multivariate predictors of treat-





Conservative surgical approach 10.3 (1.2–87.9) 0.018
Surgical approach 7 days after symptom onset 1.5 (0.4–5.7) 0.74
Staphylococcus aureus infection 5.3 (1.4–19.9) 0.013
Gram-negative bacillary infection 0.6 (0.5–0.8) 0.01
Streptococcus spp. infection 0.5 (0.1–2.1) 0.49
Antimicrobial treatment for more than 8 weeks 1.03 (0.2–4.08) 1.0
Antimicrobial treatment for more than 12 weeks 1.7 (0.5–6.02) 0.53
aConservative surgical management with retention of the prosthesis was the
only factor independently associated with treatment failure in the multivariate
analysis (OR 11.6, 95% CI 1.29–104.8, p 0.028).
TABLE 4. Univariate predictors of treatment failure among
34 cases of haematogenous prosthetic joint infection trea-
ted with a conservative surgical approach
Characteristics Relative risk (95% CI) p
ASA score ‡3 4.15 (0.4–36.7) NS
Male sex 2.2 (0.5–9.3) NS
Female sex 0.4 (0.1–1.7) NS
Diabetes mellitus 1.4 (0.2–8.5) NS
Rheumatoid arthritis 4.9 (0.4–53.2) NS
Immunosuppressiona 0.2 (0.02–2.9) NS
Staphylococcus aureus infection 3.08 (0.7–12.9) NS
Streptococcus spp. infection 1.45 (0.2–8.5) NS
Gram-negative bacillary infection 0.46 (0.3–6.9) 0.013
Primary prosthesis 0.8 (0.14–4.1) NS
Surgical approach within 7 days
of symptom onset
0.35 (0.06–1.8) NS
Antimicrobial treatment for more
than 8 weeks
0.26 (0.05–1.2) NS
ASA, American Society of Anesthesiologists score; NS, not signiﬁcant.
aImmunosuppression includes cirrhosis, malignant disease, and treatment with
immunosuppressive drugs.






























Treatment failure 1 (6.3%)
No treatment failure 14 (87.4%)
Unknown 1 (6.3%)
Treatment failure 14 (41.2%)
No treatment failure 19 (55.9%)
Unknown 1 (2.9%) P < 0.05
FIG. 1. Clinical outcome of 50 patients with acute haematogenous prosthetic joint infection (AHPJI) (24-month follow-up) according to surgical
approach. Data are presented as number (%) of episodes. Treatment failure includes: seven relapses, ﬁve persistent infections, and two infection-
related deaths.
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knee prostheses (40%, 8/20). The outcomes of the nine
patients treated only with joint aspiration was as follows: six
cases cured, two failed (one persistence and one relapse),
and one lost to follow-up.
Discussion
To our knowledge, this is the largest reported case series of
patients with AHPJI, which, in our experience, is responsible
for 10% of all PJIs. Although the incidence of this complica-
tion is unknown, it is estimated to be low; only 8% of 188
cases of prospectively reported bacterial arthritis were hae-
matogenous infections associated with prosthetic joints or
osteosynthetic material [23].
It is of note that almost half of the patients had a previous
infection at a distant site. The risk of acquiring AHPJI in
patients with orthopaedic prostheses following different dis-
tant infection is unknown, except that in a report on S. aur-
eus bacteraemia, it was as high as 34% (15/44) [6]. In that
study, 19% of patients had previous catheter-related bactera-
emia and 31% a skin and soft tissue infection, conditions that
are usually treated with a short course of antibiotics.
Because of the high risk of AHPJI in patients with S. aureus
bacteraemia, prolongation of antibiotic therapy should be
considered to prevent this complication. Prophylaxis prior to
dental procedures in patients with prosthetic joints is con-
troversial. Our data and those of previous studies [24–26]
suggest that dental work is not a risk factor for subsequent
prosthesis infection [26].
Exchange arthroplasty continues to be the standard of
treatment, particularly in chronic PJI [3–5,9,19]. However,
patients with acute infections and stable implants are consid-
ered to be appropriate candidates for a CSA, with early
debridement, replacement of the polyethylene component,
and retention of the implant, as well as active antibiotics for
at least 3 months [1,3–5,7,13,18]. In our study, the failure
rate in CSA patients was 41%, similar to the 50% reported
by Betsch et al. [27]. The cure rates of acute infections trea-
ted with a CSA show considerable variation, with success
rates ranging from as low as 23% [18,22,28–30] to higher
than 70% [15,16,18,21,31,32]. Several factors can explain
these differing results, including the deﬁnition of failure,
degree of debridement, presence of a sinus tract or prosthe-
sis loosening, and long duration of symptoms before debride-
ment, all of which are associated with higher failure rates
[3,4,14,18,27,28]. Overall, we found no differences between
patients undergoing debridement within 7 days after symp-
tom onset and those undergoing it later, but we did observe
a tendency for there to be a worse prognosis in cases of late
surgical debridement and S. aureus infection. Some authors
suggest that combined antibiotic therapy with rifampicin
results in better outcomes [13,17,31,32]; we could not evalu-
ate this, as almost all of our patients with staphylococcal
infections were treated with this combination.
The microorganism responsible for the infection can be
also a crucial factor related to outcome. In our study, the
overall failure rate in streptococcal infections was 14.3%, but
only 33.3% of them were managed with a CSA. In the litera-
ture, success rates for a CSA in streptococcal infections are
as high as 93% and 89% [12,15]. We observed no treatment
failures in Gram-negative infections, which is in accordance
with recent studies carried out with ﬂuoroquinolones, in
which these infections were successfully treated in four of
four (100%), four of six (66.6%) and 13/13 (100%) patients,
respectively [10,14,21].
In the present study, the overall failure rate in S. aureus
infections was 57.8%. Some authors [17,32,33] have
reported higher cure rates (>90%) with a CSA in cases of
acute infection. However, the sample sizes were small, and
in one of the studies [17] patients who died were classiﬁed
as non-evaluable. Other authors have reported failure rates
of 92% [29] and 69% [28]. The failure rate seems to be
particularly high in MRSA infections: Bradbury et al. [34]
recently reported an 86% failure rate in acute MRSA PJI. A
better outcome in Gram-negative infections than in S. aureus
infections could be related to the increased capacity for
bioﬁlm formation in staphylococcal infection, which can
make eradication of the microorganism difﬁcult, especially if
rifampicin is not used. The results of this study and the
literature review suggest that for acute Gram-negative and
streptococcal PJI, CSA is a safe option with high cure rates.
For staphylococcal infections, the decision to apply a CSA is
more difﬁcult, as failure rates are higher. However, patients
with infections of particularly short duration may be candi-
dates for a CSA as a ﬁrst therapeutic option. Only three of
our patients with staphylococcal infections were initially
treated with prosthesis removal, so it was impossible to
compare outcome results with those of cases treated with
a CSA. Thus, the decision should be individualized and
based on the age of the patient, surgical risk, type of infec-
tion, difﬁculty of removing the prosthesis, and methicillin
resistance. In any case, if a CSA is used, the patient should
be closely followed up to exclude persistence or relapse of
the infection, particularly after completion of antibiotic
therapy.
Together with surgery, antimicrobial therapy is a corner-
stone of treatment for PJI. Initially, the intravenous route is
preferred; nevertheless, rifampicin, quinolones, co-trimoxaz-
ole, clindamycin and linezolid have good bioavailability and
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can be used orally in bone infections [1,4,16,17]. Our poor
outcome in CSA patients cannot be attributed to the dura-
tion of the antibiotic course, as it was longer than in patients
treated with prosthesis removal.
The present study had certain limitations. First, because
of its observational nature, patients were not randomized
to any surgical modality or antibiotic treatment; hence, we
were unable to control for confounding variables such as
the tendency to use a non-CSA in younger patients with
better baseline conditions and a CSA with joint salvage in
elderly patients. Second, we deﬁned treatment failure as
persistence of infection, occurrence of a relapse due to
the same microorganism at any time during follow-up, or
occurrence of a related death. In patients with acute infec-
tion, it is difﬁcult not to attribute death to this condition,
although all four cases classiﬁed as unrelated death were
re-evaluated. On the other hand, the strengths of this
study are the prospective data collection and patient man-
agement by a specialized team in all of the participating
centres.
In conclusion, AHPJI is caused by Gram-positive cocci in
66% of cases. No factors other than a CSA were found to
be independently associated with treatment failure. However,
a CSA could be the ﬁrst tentative therapeutic approach for
acute, Gram-negative, streptococcal infections, and in some
cases with acute S. aureus infections.
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